MC1R reduces scarring and rescues stalled healing in a preclinical chronic wound model

Yonlada Nawilaijaroen,Holly Rocliffe,Shani Austin-Williams,Georgios Krilis,Antonella Pellicoro,Kanheng Zhou,Yubo Ji,Connor A Bain,Alastair M Kilpatrick,Yuhang Chen,Asok Biswas,Michael Crichton,Zhihong Huang,Stuart J Forbes,Andrea Caporali,Jenna L Cash

DOI: https://doi.org/10.1101/2022.11.30.518516

2024-04-16

Abstract:Cutaneous healing results in scarring with significant functional and psychological sequelae, while chronic non-healing wounds represent repair failure often with devastating consequences, including amputation and death. Due to a lack of effective therapies, novel interventions addressing scarring and chronic wounds are urgently needed. Here, we demonstrate that harnessing melanocortin 1 receptor with a selective agonist (MC1R-Ag) confers multifaceted benefits to wound repair. MC1R-Ag accelerates wound closure and re-epithelialization while improving wound bed perfusion and lymphatic drainage by promoting angiogenesis and lymphangiogenesis. Concomitant reductions in oxidative stress, inflammation and scarring were also observed. To evaluate the therapeutic potential of targeting MC1R in pathological healing, we established a novel murine model that recapitulates the hallmarks of human non-healing wounds. This model combines advanced age and locally elevated oxidative stress. Remarkably, topical application of MC1R-Ag restored repair, whereas disrupting MC1R signalling exacerbated the chronic wound phenotype. Our study highlights MC1R agonism as a promising therapeutic approach for scarring and non-healing wound pathologies, and our chronic wound model as a valuable tool for elucidating ulcer development mechanisms.

Pathology

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the failure of chronic wound repair and scar formation. Specifically, the study focused on the role of Melanocortin 1 receptor (MC1R) in acute and chronic wound repair. By using a selective MC1R agonist (MC1R - Ag), the researchers aimed to explore whether MC1R agonists could accelerate wound closure, promote re - epithelialization, and reduce scar formation. In addition, a new mouse chronic wound model was developed, which could simulate the key features of human chronic wounds, including the conditions of advanced age and increased local oxidative stress. Through this model, the researchers evaluated the potential efficacy of MC1R agonists in treating non - healing chronic wounds.

The study found that MC1R agonists not only accelerated the wound closure and re - epithelialization processes, but also improved the blood supply and lymphatic drainage of the wound bed by promoting angiogenesis and lymphangiogenesis, while reducing oxidative stress, inflammatory responses, and scar formation. In chronic non - healing wounds, local application of MC1R agonists restored the wound repair ability, while interfering with MC1R signal transduction exacerbated the manifestations of chronic wounds. These results indicate that MC1R agonists may be an effective method for treating scar formation and non - healing wound pathologies, and also provide a valuable tool for elucidating the mechanisms of ulcer development.